Kimberly-Clark Faces Market Concerns Over Kenvue Acquisition Despite Dividend King Status
Kimberly-Clark (KMB), a member of the elite group known as 'Dividend Kings' with over five decades of consecutive dividend growth, is currently facing bearish sentiment due to its pending acquisition of Kenvue. The deal aims to combine brands like Kleenex and Huggies with Tylenol and Band-Aid but has raised concerns about litigation risks tied to allegations that Tylenol may cause autism or ADHD. When the merger was first announced in November, shares dropped 15%, and by spring had fallen over 20% from pre-announcement levels. Although some recovery occurred since then, KMB remains down roughly 8.1%. The deal is currently under regulatory review but expected to close between now and late 2026. Despite the uncertainty, analysts argue that achieving even a portion of $2.1 billion in projected annual synergies could boost profitability significantly. Additionally, Kimberly-Clark was aware of potential legal risks before finalizing the acquisition.
Topics: Kenvue Kimberly-Clark merger regulatory review